The JIA cohort comprised three groups on the basis of therapies used: the MTX group (23.9%) included patients who used MTX without TNF inhibitors; the TNF inhibitor group (7.4%) included those who received TNF inhibitors irrespective of MTX use; and the unexposed group (68.7%) included patients who never used MTX and TNF inhibitors. The gene discussed is TNF; the disease is juvenile idiopathic arthritis.